Merck KGaA, Darmstadt, Germany
Frankfurter Straße 250
Darmstadt
64293
Germany
Tel: 49-6151-720
Fax: 49-6151-722000
Website: https://www.emdgroup.com/en
Email: service@emdgroup.com
447 articles with Merck KGaA, Darmstadt, Germany
-
Merck KGaA, Darmstadt, Germany Data at ASCO 2019 Showcase Multiple Innovative Molecules with Potential to Impact Unmet Needs in Cancer Care
5/15/2019
Merck KGaA, Darmstadt, Germany announced that data across several modalities and mechanisms targeting difficult-to-treat cancers will be presented at the 2019 American Society of Clinical Oncology Annual Meeting, May 31–June 4, Chicago, IL, US.
-
FDA Approves BAVENCIO® (avelumab) Plus INLYTA® (axitinib) Combination for Patients with Advanced Renal Cell Carcinoma
5/15/2019
EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Inc. (NYSE: PFE) announced that the US Food and Drug Administration (FDA) has approved BAVENCIO® (avelumab) in combination with INLYTA® (axitinib) for the first-line treatment of patients with advanced renal cell carcinoma (RCC).
-
The approval marks the first time the FDA has approved a checkpoint inhibitor for the treatment of advanced renal cell cancer.
-
F-star Expedites Its Transition to a Wholly-Owned Portfolio Strategy
5/14/2019
F-star, a clinical-stage biopharmaceutical company delivering tetravalent bispecific antibodies for a paradigm-shift in cancer therapy, today announced the reconfiguration of its immuno-oncology collaboration, established in 2017, with Merck KGaA, Darmstadt, Germany as it executes on its transition to a wholly-owned portfolio and builds scale and value as a world-class biopharmaceutical company.
-
EMD Serono to Present New Data on Mavenclad®, Rebif® and the Investigational Therapy Evobrutinib at the AAN Annual Meeting 2019
4/30/2019
20 abstracts will be presented during the AAN Annual Meeting 2019 to demonstrate EMD Serono's commitment and clinical development program in multiple sclerosis
-
1Q2019 Life Science Growth Announcements
4/18/2019
In the first quarter of 2019, more than 30 life science companies* announced expansions, new locations, increased funding, new trial and product launches and various other news pointing to a growing industry. -
MilliporeSigma Drives Packaging Sustainability Through New Program
4/15/2019
As part of MilliporeSigma’s commitment to reduce its environmental impact, the company has launched a new SMASH Packaging Plan
-
Entegris Issues Statement
4/8/2019
Entegris has considered its options and does not currently intend to propose to revise the terms of the Entegris-Versum merger of equals.
-
The Healthcare Business of Merck KGaA, Darmstadt, Germany Standardizes on Veeva CRM Globally to Improve Commercial Execution Across Channels
4/4/2019
Expansion in EMEA follows the business’ success with Veeva CRM throughout North America, Latin America, and Asia Pacific
-
The lynchpin to biotech and pharmaceutical drug development in the United States is arguably the greater Boston area, which includes the white hot square mile of talent and intellectual collaboration found in Kendall Square.
-
EMD Serono, a unit of Merck KGaA, Darmstadt, Germany, announced that the U.S. Food and Drug Administration (FDA) had approved Mavenclad (cladribine) for adults with relapsing-remitting multiple sclerosis (RRMS) and active secondary progressive disease (SPMS).
-
Immuno-oncology has become a key lynchpin in the pipelines of many pharmaceutical companies. The global cancer immunotherapy market is expected to more than double over the next eight years to $126.9 billion by 2026.
-
Merck KGaA, Darmstadt, Germany, and Pfizer Announce Discontinuation of Phase III JAVELIN Ovarian PARP 100 Trial in Previously Untreated Advanced Ovarian Cancer - March 19, 2019
3/20/2019
Merck KGaA, Darmstadt, Germany and Pfizer Inc. announced the discontinuation of the ongoing Phase III JAVELIN Ovarian PARP 100 study evaluating the efficacy and safety of avelumab in combination with chemotherapy followed by maintenance therapy of avelumab in combination with talazoparib,* a poly polymerase inhibitor, versus an active comparator in treatment-naïve patients with locally advanced or metastatic ovarian cancer.
-
The trial, which paired a checkpoint inhibitor and PARP inhibitor, was not likely to hit endpoints. It was the second ovarian cancer trial failure for the two companies in six months.
-
Merck KGaA, Darmstadt, Germany, and Pfizer Announce Discontinuation of Phase III JAVELIN Ovarian PARP 100 Trial in Previously Untreated Advanced Ovarian Cancer
3/19/2019
Merck KGaA, Darmstadt, Germany announced the discontinuation of the ongoing Phase III JAVELIN Ovarian PARP 100 study evaluating the efficacy and safety of avelumab in combination with chemotherapy followed by maintenance therapy of avelumab in combination with talazoparib,* a poly polymerase inhibitor, versus an active comparator in treatment-naïve patients with locally advanced or metastatic ovarian cancer.
-
Iktos Announces Collaboration with Merck KGaA, Darmstadt, Germany, for Use of Iktos AI Technology across Three Drug Discovery Projects
3/14/2019
Collaboration agreement enables Merck KGaA, Darmstadt, Germany access to Iktos AI technology across three drug discovery projects
-
Merck KGaA, Darmstadt, Germany, Announces Collaboration With Iktos for Generative Artificial Intelligence (AI) Technology
3/14/2019
Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced a collaboration agreement with Iktos, for the use of its generative modelling artificial intelligence (AI) technology, in order to facilitate the rapid and cost-effective discovery and design of promising new compounds.
-
BioXcel Therapeutics Announces Addition of Merck KGaA, Darmstadt, Germany, and Pfizer to Clinical Collaboration with Nektar for Development of Triple-combination Therapy in Pancreatic Cancer
3/4/2019
BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI) today announced the addition of Merck KGaA, Darmstadt, Germany, which operates its biopharmaceutical business as EMD Serono in the USA and Canada, and Pfizer Inc. (NYSE: PFE) to its Nektar Therapeutics (Nasdaq: NKTR) clinical collaboration to evaluate a novel triple combination therapy in pancreatic cancer.
-
Topping an offer from Billerica, Massachusetts-based company Entegris, Darmstadt, Germany-based Merck KGaA offered an unsolicited $5.9 billion to acquire Versum Materials.
-
Pivotal Phase III Data for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) in Advanced Renal Cell Carcinoma Published in the New England Journal of Medicine
2/16/2019
Merck KGaA, Darmstadt, Germany announced the publication of results from an interim analysis of the pivotal JAVELIN Renal 101 trial online in the New England Journal of Medicine.